Clinical

Venetoclax is a small molecule inhibitor of the BCL-2 protein, which potentially represents a new way of treating blood cancers, in this article, specifically for chronic lymphocytic leukemia (CLL). Regulatory applications for venetoclax are planned for submission to the U.S. Food and Drug Administration (FDA) and European Medicines Agency